ESCMID COVID-19 Web Symposia

Don’t miss the ESCMID COVID-19 Websymposia!

The next websymposia, covering COVID-19 Immunity starts this evening at 17:00, with perspectives from Prof. Andrew Pollard (chief Investigator leading the development of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2), Dr. Steve Pascolo (developer of mRNA vaccine technologies) and Prof. Florian Krammer (Professor of Vaccinology at the Icahn School of Medicine at Mt. Sinai).

View the programme of upcoming websymposia and register on the ESCMID Website.

› Read more

Pre-ECCMID Days – Register now!

The 5 Pre-ECCMID Days are now open for registration!

The themed online days are available for registration individually, but are also included with every full registration for ECCMID.

Visit the ECCMID website to find out more and to register!

› Read more

ESCMID Vlogs

Have you watched the new ESCMID Vlogs yet?

Listen to the thoughts of members of the ESCMID community as they give their thoughts on the current state of the ID/CM community, COVID-19 and ECCMID. 

More Vlogs are still to come on the ESCMID YouTube Channel.

› Read more

ESCMID YouTube Channel: Catch the Websymposia!

Have you subscribed to the ESCMID YouTube channel? Find Vlogs, ECCVID sessions, as well as the replays of the COVID-19 Websymposia available for on-demand viewing.

Visit the ESCMID YouTube channel to view and subscribe!

› Read more

ESCMID Emerging Infections Task Force (EITaF)

Are you subscribed to the EITaF Outbreak News?

Visit the EITaF Outbreak News page to read the regular updates on emerging infections, including COVID-19. 

Log in to your ESCMID Account and change your newsletter settings to be alerted by email when a new piece of Outbreak News is published!

› Read more

CMI highlight: Pulmonary long-term consequences of COVID-19 infections after hospital discharge

COVID-19 survivors are reporting residual abnormalities after discharge from the hospital. Limited information is available about this stage of recovery or the lingering effects of the virus on pulmonary function and inflammation. The aim of this study was to describe lung function and to identify biomarkers in serum and induced sputum samples from patients recovering from COVID-19 hospitalisation.

A total of 100 patients from Spanish hospitals with respiratory function tests were included in this study. From the results obtained with this study, it is shown that a high proportion of severely affected COVID-19 patients show impairment in diffusion capacity of the lung for carbon monoxide (DLCO) measurements in the first few months after symptoms onset. Although its long-term impact is still unknown, DLCO could be considered a useful tool to identify individuals at risk for pulmonary sequelae. It will be necessary to follow these patients for longer periods of time to detect needs and appropriately manage potential lung damage.

› Read more